Meeting
2023 ASCO Annual Meeting
Evaluation of cachexia and outcomes in patients with aggressive B-cell non-Hodgkin lymphoma.
Authors
Nicholas Demetriou
Feinberg School of Medicine, Northwestern University, Chicago, IL
Nicholas Demetriou , Madelyn Burkart , Ashwin Sunderraj , Shuo Ma , Jane N. Winter , Leo I. Gordon , Reem Karmali , Ishan Roy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6624)
DOI
10.1200/JCO.2023.41.16_suppl.6624
Abstract #
6624
Poster Bd #
116
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
First Author: Cariad Chester
Poster
2024 ASCO Annual Meeting
Estimating adult cancer cachexia prevalence and impact on survival in the US: Real-world data analysis.
First Author: Eric Roeland
Poster
2024 ASCO Annual Meeting
Neurofilament light chains: A biomarker for vincristine-related neuropathy.
First Author: Gretchen A McNally
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of TP53, RB1, and PTEN mutations on overall survival in metastatic prostate cancer: A multi-center study via the Guardian Research Network.
First Author: Mohammad Arfat Ganiyani